Adult Vaccines Market - by Vaccine (Influenza, Tetanus/Diphtheria/Pertussis, Varicella, Human Papillomavirus, Zoster, Measles/mumps/Rubella, Pneumococcal, Hepatitis, and Others), by Vaccine Type (Monovalent and Multivalent), by Technology (Live Attenuated Vaccines, Inactivated Viral or Bacterial Vaccines, Toxoid Vaccines, Recombinant Vaccines, and Conjugate Vaccines), and by Region - Global Industry Insights, and Forecast till 2025

  • Published On : Apr 2018 |
  • Pages : 150 Pages |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Global Adult Vaccines Market – A Vital Step towards Disease Prevention

Vaccines refer to the biological preparation that improves immunity to fight against a particular disease. Vaccines comprise suspensions formulated from weakened, killed or fragmented microorganisms, toxins or antibodies that are administered to a patient, with a primary intention to prevent a disease. Vaccines offer active immunity against specific harmful and disease causing agents by stimulating the immune system to attack the agent. Vaccines helps to protect individuals against serious and fatal diseases such as influenza and measles among others. Adult immunization that includes administration of licensed vaccine provided to patients aged 18 years and older, for medical indications. Vaccines are routinely administered to eliminate the infectious diseases among infants and children, however the Centers of Disease Control & Prevention (CDC), 2016, also recommends adults to periodically take up vaccination, referred to as adult vaccines. According to the CDC 2015, 30% of the patients from mission Healthy People 2020 opted for Shingles vaccine and were reported to be safe from preventable illness.

The global Adult Vaccines Market was valued at US$ 12,806.49 million in 2017 and is expected to witness a robust CAGR of 7.1% over the forecast period (2017 - 2025).

Figure 1. Global Adult Vaccines Market in (US$ Mn), by Region, 2017

adult vaccine market

Source: Coherent Market Insights (2018)

Factors such as increasing number of government initiatives to prevent certain diseases and epidemic caused due to vaccine-preventable diseases. Additionally, increasing number of countries are conducting national immunization programs to provide vaccination and promote awareness regarding advantages of vaccination to fight fatal diseases with natural immunity among adults as well as children. For instance, in 2015, the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA) and the National Institutes of Health (NIH) partnered with the U.S. Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA) to support the advanced development of new and better influenza vaccines, as a part of inter-agency government effort in the U.S. Among the middle-income and emerging economies, relevant Indian government funding agencies such as Department of Biotechnology (DBT) and The Indian Council of Medical Research (ICMR) are scaling up their investments in research and development associated to vaccine development. For instance, in 2015, the Department of Biotechnology projected a funding of US$ 2.95 million for Malaria Vaccine Initiative, to develop vaccine against Plasmodium falciparum and P. vivax. On the other hand, growing awareness among the populace regarding prevention of diseases facilitated by vaccines is expected to augment the market growth over the forecast period. For instance, according to the Centers for Disease Control and Prevention, 2015, flu vaccinations prevented around 1.9 million flu illnesses, 966,000 flu-associated medical visits, and around 67,000 flu-associated hospitalizations, representing 6.5% lowering of disease burden. Moreover, according to a study from the Society for Risk Analysis, 2016, GDP loss of a pandemic outbreak in the U.S. was recorded between US$ 34.4 billion and US$ 45.3 billion. However, a large population not being vaccinated poses as a restraint for growth of the market. For instance, according to National Health Interview Survey conducted by the Centers of Disease Control & Prevention (CDC) 2015, more than 4 out of 5 people did not report for Tdap vaccination in the U.S. and over one-third of the participants did not report for pneumococcal vaccination.

Among region, the market in North America held a dominant position in the global adult vaccines market in 2016. This is attributed to increasing investments facilitated by government as well as the manufacturers consistently focusing on promoting immunization in the U.S. For instance, in 2015, The Centers for Medicare & Medicaid Services (CMS), in alignment with the Centers for Disease Control and Prevention (CDC) introduced a five-year initiative named Healthy People 2020, to improve adult immunization as well as reduce the disparity rates caused majorly due to pneumonia, shingles, and influenza by working directly with physicians and provider offices, as well as with home health agencies, hospitals, beneficiaries and others under the guidance of Health Service Advisory Group (HSAG). Moreover, favorable Medicare coverage for adult vaccination in the U.S. also poses as a key factor favoring growth of the adult vaccines market. For instance, National Health Interview Survey (NHIS), 2015, reports an increase of 2.8% increased risk for pneumococcal disease among adults aged 19-64 years. The market in Asia Pacific is expected to witness significant traction, owing to extensive research conducted by the local players to cater to the increasing prevalence of diseases for which vaccines have not been developed. For instance, in January 2018, Bharat Biotech, an India-based company, was awarded with prequalification from the World Health Organization to develop world’s first rotavirus vaccine ROTAVAC.

Market players are engaged in development vaccines to cater to diseases with high epidemic

Market players are increasingly focusing on developing vaccines that caters to diseases with highest probability of causing an epidemic. For instance, in February 2017, an India-based drug firm, Cipla, in collaboration with Serum Institute of India, introduced Hepatitis B vaccine for adults in the country. The disease affects chronically over 40 million people in the country, as per India’s Universal Immunization Programme. Moreover, Dynavax Technologies Corporation received FDA approval in 2018, for its two-dosed Hepatitis-B vaccine indicated for adults aged 18 years and older.

Key players operating in the global adult vaccines market include GlaxoSmithKline Plc, Merck & Co., Sanofi Pasteur, Pfizer, Inc., CSL Limited, Johnson & Johnson, Serum Institute of India, Medimmune, and AstraZeneca Plc.

Vaccination and immunization is aids in prevention of diseases among adults and children. Vaccines are biological suspensions that contain an agent that resembles the disease causing microorganisms and are often made from inactivated microbes, toxins or surface proteins. The active agents present in the vaccine stimulates body’s immune system to recognize the disease causing agent as 'foreign substance' and develop antibodies against it. Vaccines are a preferable and highly recommended preventive measure against certain severe diseases, however, have mild side effects.

Market Dynamics

Development of vaccines for various new diseases and rising awareness regarding advantages of preventive medication are the two prominent factors supporting growth of the market. For instance, according to the Centers for Disease Control and Prevention, 2015, flu vaccinations prevented around 1.9 million flu illnesses, 966,000 flu-associated medical visits, and around 67,000 flu-associated hospitalizations, representing 6.5% lowering of disease burden. However, high complexity in cost of manufacturing a vaccine is one of the major factors negatively affecting growth of the market.

Key features of the study:

  • This report provides in-depth analysis of adult vaccines market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017 – 2025), considering 2017 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global adult vaccines market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments and strategies, and future plans
  • Key companies covered as a part of this study includes GlaxoSmithKline Plc, Merck & Co., Sanofi Pasteur, Pfizer, Inc., CSL Limited, Johnson & Johnson, Serum Institute of India, Medimmune, and AstraZeneca Plc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
  • The global adult vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the adult vaccines market

Detailed Segmentation:

  • Global Adult Vaccines Market, By Vaccine:
    • Influenza
    • Tetanus, Diphtheria, Pertussis (Td/Tdap)
    • Varicella
    • Human Papillomavirus
    • Zoster
    • Measles, Mumps, Rubella (MMR)
    • Pneumococcal
    • Hepatitis
    • Others
  • Global Adult Vaccines Market, By Vaccine Type:
    • Monovalent
    • Multivalent
  • Global Adult Vaccines Market, By Technology:
    • Live Attenuated Vaccines
    • Inactivated Viral/Bacterial Vaccines
    • Toxoid Vaccines
    • Recombinant Vaccines
    • Conjugate Vaccines
  • Global Adult Vaccines Market, By Geography:
    • North America
      • By Vaccine:
        • Influenza
        • Tetanus, Diphtheria, Pertussis (Td/Tdap)
        • Varicella
        • Human Papillomavirus
        • Zoster
        • Measles, Mumps, Rubella (MMR)
        • Pneumococcal
        • Hepatitis
        • Others
      • By Vaccine Type:
        • Monovalent
        • Multivalent
      • By Technology:
        • Live Attenuated Vaccines
        • Inactivated Viral/Bacterial Vaccines
        • Toxoid Vaccines
        • Recombinant Vaccines
        • Conjugate Vaccines
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Vaccine:
        • Influenza
        • Tetanus, Diphtheria, Pertussis (Td/Tdap)
        • Varicella
        • Human Papillomavirus
        • Zoster
        • Measles, Mumps, Rubella (MMR)
        • Pneumococcal
        • Hepatitis
        • Others
      • By Vaccine Type:
        • Monovalent
        • Multivalent
      • By Technology:
        • Live Attenuated Vaccines
        • Inactivated Viral/Bacterial Vaccines
        • Toxoid Vaccines
        • Recombinant Vaccines
        • Conjugate Vaccines
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Vaccine:
        • Influenza
        • Tetanus, Diphtheria, Pertussis (Td/Tdap)
        • Varicella
        • Human Papillomavirus
        • Zoster
        • Measles, Mumps, Rubella (MMR)
        • Pneumococcal
        • Hepatitis
        • Others
      • By Vaccine Type:
        • Monovalent
        • Multivalent
      • By Technology:
        • Live Attenuated Vaccines
        • Inactivated Viral/Bacterial Vaccines
        • Toxoid Vaccines
        • Recombinant Vaccines
        • Conjugate Vaccines
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Vaccine:
        • Influenza
        • Tetanus, Diphtheria, Pertussis (Td/Tdap)
        • Varicella
        • Human Papillomavirus
        • Zoster
        • Measles, Mumps, Rubella (MMR)
        • Pneumococcal
        • Hepatitis
        • Others
      • By Vaccine Type:
        • Monovalent
        • Multivalent
      • By Technology:
        • Live Attenuated Vaccines
        • Inactivated Viral/Bacterial Vaccines
        • Toxoid Vaccines
        • Recombinant Vaccines
        • Conjugate Vaccines
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Vaccine:
        • Influenza
        • Tetanus, Diphtheria, Pertussis (Td/Tdap)
        • Varicella
        • Human Papillomavirus
        • Zoster
        • Measles, Mumps, Rubella (MMR)
        • Pneumococcal
        • Hepatitis
        • Others
      • By Vaccine Type:
        • Monovalent
        • Multivalent
      • By Technology:
        • Live Attenuated Vaccines
        • Inactivated Viral/Bacterial Vaccines
        • Toxoid Vaccines
        • Recombinant Vaccines
        • Conjugate Vaccines
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Vaccine:
        • Influenza
        • Tetanus, Diphtheria, Pertussis (Td/Tdap)
        • Varicella
        • Human Papillomavirus
        • Zoster
        • Measles, Mumps, Rubella (MMR)
        • Pneumococcal
        • Hepatitis
        • Others
      • By Vaccine Type:
        • Monovalent
        • Multivalent
      • By Technology:
        • Live Attenuated Vaccines
        • Inactivated Viral/Bacterial Vaccines
        • Toxoid Vaccines
        • Recombinant Vaccines
        • Conjugate Vaccines
      • By Country:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • GlaxoSmithKline Plc *
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Merck & Co., Inc.
    • Sanofi Pasteur
    • Pfizer, Inc.
    • CSL Limited
    • Johnson & Johnson
    • Serum Institute of India
    • Medimmune
    • AstraZeneca Plc

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Vaccine
      • Market Snippet, By Vaccine Type
      • Market Snippet, By Technology
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Key Highlights
    • Market Trends
    • PEST Analysis
    • Government & Non-Government Initiatives
    • Epidemiology
  4. Global Adult Vaccines Market, By Vaccine, 2015 – 2025, (US$ Million)
    • Introduction
      • Market Share Analysis, 2017 and 2025 (%)
      • Y-o-Y Growth Analysis, 2016 – 2025
      • Segment Trends
    • Influenza
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
    • Tetanus, Diphtheria, Pertussis (Td/Tdap)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
    • Varicella
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
    • Human Papillomavirus
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
    • Zoster
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
    • Measles, Mumps, Rubella (MMR)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
    • Pneumococcal
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
    • Hepatitis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
  5. Global Adult Vaccines Market, By Vaccine Type, 2015 – 2025, (US$ Million)
    • Introduction
      • Market Share Analysis, 2017 and 2025 (%)
      • Y-o-Y Growth Analysis, 2016 – 2025
      • Segment Trends
    • Monovalent
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
    • Multivalent
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
  6. Global Adult Vaccines Market, By Technology, 2015 – 2025, (US$ Million)
    • Introduction
      • Market Share Analysis, 2017 and 2025 (%)
      • Y-o-Y Growth Analysis, 2016 – 2025
      • Segment Trends
    • Live Attenuated Vaccines
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
    • Inactivated Viral/Bacterial Vaccines
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
    • Toxoid Vaccines
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
    • Recombinant Vaccines
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
    • Conjugate Vaccines
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
  7. Global Adult Vaccines Market, By Region, 2017 – 2025, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2017 and 2025 (%)
      • Y-o-Y Growth Analysis, For Region, 2016 – 2025
    • North America
      • Market Size and Forecast, By Vaccine, 2015 – 2025, (US$ Million)
      • Market Size and Forecast, By Vaccine Type, 2015 – 2025, (US$ Million)
      • Market Size and Forecast, By Technology, 2015 – 2025, (US$ Million)
      • Market Size and Forecast, By Country, 2015 – 2025, (US$ Million)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Vaccine, 2015 – 2025, (US$ Million)
      • Market Size and Forecast, By Vaccine Type, 2015 – 2025, (US$ Million)
      • Market Size and Forecast, By Technology, 2015 – 2025, (US$ Million)
      • Market Size and Forecast, By Country, 2015 – 2025, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Vaccine, 2015 – 2025, (US$ Million)
      • Market Size and Forecast, By Vaccine Type, 2015 – 2025, (US$ Million)
      • Market Size and Forecast, By Technology, 2015 – 2025, (US$ Million)
      • Market Size and Forecast, By Country, 2015 – 2025, (US$ Million)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Vaccine, 2015 – 2025, (US$ Million)
      • Market Size and Forecast, By Vaccine Type, 2015 – 2025, (US$ Million)
      • Market Size and Forecast, By Technology, 2015 – 2025, (US$ Million)
      • Market Size and Forecast, By Country, 2015 – 2025, (US$ Million)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of APAC
    • Middle East
      • Market Size and Forecast, By Vaccine, 2015 – 2025, (US$ Million)
      • Market Size and Forecast, By Vaccine Type, 2015 – 2025, (US$ Million)
      • Market Size and Forecast, By Technology, 2015 – 2025, (US$ Million)
      • Market Size and Forecast, By Country, 2015 – 2025, (US$ Million)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Vaccine, 2015 – 2025, (US$ Million)
      • Market Size and Forecast, By Vaccine Type, 2015 – 2025, (US$ Million)
      • Market Size and Forecast, By Technology, 2015 – 2025, (US$ Million)
      • Market Size and Forecast, By Country, 2015 – 2025, (US$ Million)
        • South Africa
        • Central Africa
        • North Africa
  8. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
    • Company Profiles
      • GlaxoSmithKline Plc
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Merck & Co., Inc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Sanofi Pasteur
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Pfizer, Inc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • CSL Limited
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Johnson & Johnson
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Serum Institute of India
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Medimmune
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • AstraZeneca Plc
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
  9. Section
    • Analyst Views
  10. Section
    • References
    • Research Methodology
    • About Us and Sales Contact

*Browse 34 market data tables and 38 figures on "Adult Vaccines Market - Global forecast to 2025”.

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.